AI Consensus Investment Thesis
Roche Holding (ROP) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY380 CHF
+6.4%+8.9% incl. dividends5-Year
BUY491 CHF
+37.5%+54.1% incl. dividendsLatest flagship insight
Currency Drag Masks Biopharma Expansion As Metabolic Optionality Drives Valuation Recovery
Research reveals sharp divergence between optical headline stagnation and resilient constant-currency expansion. The primary driver is robust commercial volume in newer blockbusters paired with late-stage metabolic optionality, while persistent Swiss franc strength and looming post-2028 loss-of-exclusivity cliffs represent the decisive structural frictions across the forecast horizon.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Superintelligence (Anthropologist), Machiavelli (Insider), Warren Buffett (Value Purist), Ray Dalio (Strategist), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), J.P. Morgan (Titan), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Roche Holding at the forecast anchor (2026-09-18): $16,165 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 2.3% net dividend yield for Roche Holding.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in CHF; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (CHF) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 361.24 | +1.25% | +1.25% | Commercial momentum across Vabysmo and subcutaneous oncology formulations supports defensive accumulation into year-end. However, ongoing safe-haven Swiss franc strength and high sovereign yields temper near-term valuation multiples, resulting in measured baseline equity appreciation. |
| Q1 2027 | 365.74 | +1.25% | +2.51% | Full-year results confirm robust constant-currency operating expansion alongside another dividend increase. The seasonal ex-dividend price adjustment and currency translation drag partially offset underlying operational enthusiasm, keeping net price movement modest across Swiss trading desks. |
| Q2 2027 | 374.92 | +2.51% | +5.08% | Advancing Phase Three enrollment for incretin candidates and positive oncological presentations at medical congresses bolster pipeline sentiment. Expanding adoption of subcutaneous biologics stabilizes pharmaceutical operating margins, driving steady institutional demand as market participants digest macroeconomic crosscurrents. |
| Q3 2027 | 379.66 | +1.26% | +6.41% | Mid-year financial disclosures demonstrate solid diagnostics reagent cash flow and resilient specialty drug volumes. However, headlines regarding US Medicare price negotiations and European biosimilar competition introduce valuation friction, leading to tight consolidation near prevailing levels. |
| Q4 2027 | 387.50 | +2.07% | +8.61% | Regulatory filing acceptances for key oncology line extensions and encouraging biomarker data stimulate defensive investment. Global monetary tightening continues to favor high-free-cash-flow pharmaceutical champions over speculative biotechs, sustaining modest upward trajectory into year-end portfolio positioning. |
| Q1 2028 | 391.05 | +0.92% | +9.60% | Fiscal 2027 results highlight resilient cash conversion and another dividend increase. The seasonal dividend payout mechanically reduces the quoted price, while the start of negotiated pricing under US Medicare frameworks keeps institutional multiples disciplined. |
| Q2 2028 | 400.86 | +2.51% | +12.35% | Interim clinical readouts for enicepatide and trontinemab generate commercial optimism, confirming pipeline vitality. Maturing launch products comfortably replace off-patent oncology attrition, enabling the stock to recover post-dividend declines and post steady operational price gains. |
| Q3 2028 | 407.90 | +1.75% | +14.32% | Diagnostics automated testing expansion across North America and Europe stabilizes division operating profits above historical averages. While persistent Swiss franc translation friction caps reported earnings acceleration, consistent constant-currency execution provides reliable valuation support. |
| Q4 2028 | 412.01 | +1.01% | +15.47% | Investor focus turns toward looming 2029 US tariff policy transitions and impending biologic patent expirations. High clinical R&D spending on metabolic outcome trials dampens quarterly operating margin expansion, producing a cautious, sideways trading pattern. |
| Q1 2029 | 416.83 | +1.17% | +16.83% | Annual disclosures for 2028 confirm underlying revenue growth and reliable cash generation, supporting the board's progressive dividend hike. Standard ex-dividend cash detachment is gradually absorbed by income-oriented institutional buyers seeking balance-sheet safety. |
| Q2 2029 | 427.29 | +2.51% | +19.76% | Pivotal Phase Three metabolic trial readouts establish competitive parity with market benchmarks, removing substantial pipeline skepticism. Sell-side analysts incorporate commercial incretin revenues into valuation models, sparking solid multiple expansion across European equity markets. |
| Q3 2029 | 435.48 | +1.92% | +22.05% | Global regulatory filings for enicepatide shift investor attention to pre-commercial scale-up and supply chain readiness. Emerging biosimilar competition against legacy intravenous formulations is effectively cushioned by rapid subcutaneous patient conversion, preserving quarterly profitability. |
| Q4 2029 | 440.28 | +1.10% | +23.40% | Preparations for commercial cardiometabolic launches accelerate alongside expanded diagnostics hospital contracts. Broader macroeconomic rotations into cash-generative healthcare assets support share prices, though cautious sentiment ahead of major patent expiries keeps valuation gains measured. |
| Q1 2030 | 445.93 | +1.28% | +24.98% | Full-year 2029 financial results show core operating margins holding above thirty-two percent despite statutory pricing pressure. The annual dividend increase reaffirms shareholder yield, while domestic manufacturing investments insulate operations from international trade friction. |
| Q2 2030 | 452.58 | +1.49% | +26.84% | Regulatory approvals for enicepatide in key Western markets unlock initial commercial prescription revenues. Early prescription uptake across commercial payer channels confirms launch viability, driving positive earnings revisions that comfortably outpace residual biosimilar erosion. |
| Q3 2030 | 460.78 | +1.81% | +29.14% | Commercial manufacturing scale-up for peptide synthesis and automated diagnostic systems lowers unit production costs. Stable healthcare spending across international territories cushions net operating income against ongoing domestic price renegotiations, sustaining moderate capital appreciation. |
| Q4 2030 | 468.56 | +1.69% | +31.32% | Accelerating cardiometabolic sales and expanding neurology indications diversify the consolidated earnings foundation. Management maintains conservative leverage and disciplined capital returns, prompting institutional long-term asset managers to expand core equity allocations into year-end. |
| Q1 2031 | 473.73 | +1.10% | +32.77% | Reporting for fiscal 2030 demonstrates record free cash flow generation and successful absorption of major patent transitions. Another progressive dividend hike rewards shareholders, while the predictable ex-dividend price adjustment is rapidly absorbed by persistent institutional buying. |
| Q2 2031 | 482.76 | +1.91% | +35.30% | Commercial scale in metabolic therapies combines with high-margin automated diagnostics to generate strong operational cash conversion. Second-generation oncology assets progress smoothly through clinical development, maintaining high visibility over medium-term corporate earnings compounding. |
| Q3 2031 | 490.68 | +1.64% | +37.52% | Terminal period performance confirms a successfully navigated five-year replacement cycle. High-margin specialty therapeutics and diagnostic platform integration establish an enduring cash compounder, settling equity valuation at an equilibrium multiple that rewards long-term capital providers. |
The core investment thesis centers on a durable replacement cycle where expanding commercial blockbusters and high-throughput diagnostics generate sufficient operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry to overcome patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry on legacy biologics. While reported Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry financial statements optically compress performance, underlying operational volume compounds at mid-single-digit constant-currency rates. Valuation sensitivity remains elevated because the non-voting equity certificate trades near nineteen times core earnings rather than a perceived bargain multiple. The primary counterargument highlights approaching patent walls on key immunology and oncology franchises alongside statutory US Medicare price negotiation and structural safe-haven currency translation drag.
Key insights
- Subcutaneous drug reformulations and proprietary diagnostic instrumentation establish high clinical switching barriers that defend gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and delay biosimilar erosion across hospital networks.
- Acquired incretin assets provide unpriced cardiometabolic optionality, yet commercial viability depends on pivotal Phase Three tolerability parity rather than headline weight-loss efficacy.
- Disconnect between constant-currency profit expansion and reported Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry results will persist until foreign exchange headwinds abate and domestic cost matching improves.
The company acts like an elite cash generator whose headline numbers look sluggish mainly because of a strong Swiss currency. Beneath that currency curtain, newer medicines and automated diagnostic machines are selling well and replacing older off-patent treatments. While drug price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry and patent expiries remain real challenges, steady demand and a disciplined balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry keep the dividend well protected and support measured long-term growth.
Key insights
- Newer blockbuster treatments and hospital lab testing contracts reliably protect overall cash flow against generic competition.
- Experimental obesity and brain drugs offer substantial future upside if late-stage clinical safety trials succeed.
- A strong Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry continues reducing foreign earnings when converted into local currency for reporting.
Deep Dive
Prevailing market consensus treats the business as an ex-growth defensive bond proxybond proxyAn equity or other asset valued partly for stable income and therefore often sensitive to changes in bond yields.View full glossary entry burdened by looming patent expiries on foundational biologics, US Medicare price negotiation overhang, and relentless Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry translation friction. Sell-side sentiment assumes newer launches cannot outpace patent erosion, while external commentary largely writes off its emerging obesity and Alzheimer's pipeline as tardy, speculative bets facing entrenched global incumbents.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats the business as an ex-growth defensive bond proxybond proxyAn equity or other asset valued partly for stable income and therefore often sensitive to changes in bond yields.View full glossary entry burdened by looming patent expiries on foundational biologics, US Medicare price negotiation overhang, and relentless Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry translation friction. Sell-side sentiment assumes newer launches cannot outpace patent erosion, while external commentary largely writes off its emerging obesity and Alzheimer's pipeline as tardy, speculative bets facing entrenched global incumbents.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value through modest underpricing, mistaking optical currency translation drag for operational decay. Analytical edge stems from recognizing that constant-currency operating profit expands robustly as second-wave blockbusters and automated diagnostics fully neutralize biosimilar erosion. However, uncritical claims of a deep valuation discount are flawed: vendor screens erroneously double trailing earnings, masking that the non-voting certificate trades around nineteen times core earnings rather than thirteen times. True alpha lies in unmodeled cardiometabolic and neurological pipeline optionality against durable through-cycle cash flow.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst arrives across 2027 and 2028 through pivotal Phase Three readouts for dual-incretin enicepatide and regulatory filings for oral SERD giredestrant. Concurrently, as foreign exchange base effects lap, reported Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry operating profit will inflect positively. Hard-to-ignore clinical registration data will force sell-side analysts to incorporate metabolic peak sales into discounted cash flow models, confirming pipeline replacement velocity and prompting institutional multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Low Steady
- Cycle position
- Growing Awareness
Reports agree on low realized volatility and defensive balance-sheet stability, but diverge sharply on valuation cycle positioning. Some identify an unpriced turnaround poised for early discovery, while others warn that recent multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry already prices in unproven late-stage pipeline optionality.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop of restrictive monetary policy, sticky inflation, and elevated geopolitical volatility represents a mixed setup. Inelastic healthcare demand protects core operating cash generation, and a conservative balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry insulates financing. However, persistent safe-haven Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry strength creates enduring translation drag on foreign earnings, while high risk-free discount rates restrain the valuation multiples investors pay for defensive yields.
Advisor Disagreement
What do our AI Advisors disagree about most? Analytical disagreement centers on valuation baselines and the durability of the patent bridge. One perspective argues that the non-voting equity certificate is fundamentally undervalued at a perceived thirteen times earnings, expecting multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry toward historical peaks as cardiometabolic assets de-risk. Conversely, the skeptical view proves that vendor data double-counts trailing figures and that the certificate trades near nineteen times core earnings, leaving little margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry against approaching Ocrevus patent expiries. Resolving this tension requires tracking whether reported Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry earnings inflect positive in 2027 and whether Phase Three obesity trials confirm competitive tolerability.
Base-Case Forces
Event Risk ScoreVery Low9/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Commercial expansion of core specialty blockbusters | Competitive Positioning | +20% | +22% | High-margin commercial therapies anchored by Vabysmo, Phesgo, Ocrevus, and Hemlibra generate double-digit constant-currency growth, outpacing legacy biologic erosion. Subcutaneous lifecycle formulations protect market share by shifting patient administration away from hospital infusion chairs. This volume expansion sustains consolidated gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above seventy-three percent, securing robust operational cash flow through the patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry. |
| Incretin franchise advancement and pipeline rejuvenation | Innovation And Product | +17% | +16% | Advancement of dual-incretin enicepatide alongside oral candidate CT-996 into Phase Three registration trials unlocks long-term cardiometabolic optionality. Demonstrating competitive weight-loss efficacy and manageable tolerability positions the business to capture meaningful market share in an expanding metabolic domain. Successful commercial execution will provide a durable second growth pillar, expanding forward terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry and driving multiple re-rating. |
| Integrated diagnostics platform and reagent compounding | Operational Efficiency | +11% | +12% | An unmatched global installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry of automated laboratory platforms locks hospital networks into multi-year proprietary reagent contracts. This razor-and-blade model delivers non-cyclical, high-margin consumable cash flow that buffers pharmaceutical patent volatility. As clinical chemistry, molecular assays, and companion biomarker testing scale globally, recurring diagnostic earnings compound steadily, insulating consolidated operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry against broader macroeconomic downcycles. |
| Disciplined capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry and dividend compounding | Capital Allocation | +9.0% | +8.0% | Generating over fourteen billion francs in annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry underpins an unbroken four-decade track record of growing Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry dividends. Conservative balance-sheet stewardship prioritizes self-funded internal clinical development and selective bolt-on acquisitionsbolt on acquisitionsPurchases of smaller businesses intended to add products, capabilities, customers, or geographic reach to an existing operation.View full glossary entry rather than dilutive mega-mergers. This dependable capital distribution policy establishes an enduring valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry, attracting defensive institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry during volatile global interest rate regimes. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Structural Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry foreign exchange drag | Macroeconomic And Macrofinancial | -11% | -14% | Persistent safe-haven strength of the Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry creates a perpetual negative translation wedge on reported financials. Generating over eighty percent of revenues in depreciating foreign currencies while maintaining substantial domestic research and corporate overhead mechanically compresses reported top-line expansion and nominal earnings. Constant-currency growth consistently fails to convert into equivalent reported franc figures, muting headline equity returns. |
| Impending loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry patent cliffs | Competitive Positioning | -10% | -12% | Expiring patent protections on foundational blockbusters, including Perjeta, Kadcyla, and Actemra, alongside approaching patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry on Ocrevus, create continuous structural revenue erosion. Aggressive biosimilar discounting forces the business to reinvest billions into clinical research merely to replace lost revenues. This relentless replacement cycle constrains net revenue acceleration and caps consolidated pharmaceutical operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion. |
| US and global healthcare pricing retrenchment | Regulatory | -9.0% | -10% | Mandatory Medicare drug price negotiations under the US Inflation Reduction Act, alongside European single-payer containment and Chinese volume-based procurement, squeeze net realized pharmaceutical prices. Statutory price caps on mature biologics degrade gross-to-net realizations in the company's most profitable geographic markets. This intensifying regulatory intervention limits long-term pricing flexibility, compressing terminal cash flows across mature commercial lines. |
| Escalating late-stage clinical trial expenditures | Operational Efficiency | -7.0% | -8.0% | Funding expansive global Phase Three registration trials across cardiometabolic, oncological, and neurological indications elevates research and development intensity toward twenty-two percent of revenue. Escalating patient recruitment costs and complex trial protocols consume substantial operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry before commercial revenues materialize. This heavy reinvestment burden temporarily suppresses free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry, deferring operational margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry until commercialization milestones arrive. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Catastrophic late-stage obesity pipeline failure | 28% | -23% | Registrational trials for enicepatide or oral incretin CT-996 could uncover unexpected hepatotoxicity or severe gastrointestinal discontinuation rates during Phase Three escalation by 2027. Clinical termination would instantly wipe out acquired Carmot goodwill and extinguish market expectations of a multi-billion-franc cardiometabolic franchise. Probability remains under fifty percent given clean early-phase tolerability data, but biological development attrition poses a severe tail threat. |
| Radical transatlantic healthcare price cap mandate | 25% | -20% | Coordinated legislative escalation in the United States and Europe could aggressively expand mandatory price negotiations to capture newer biologics and subcutaneous reformulations before 2028. Enforcing draconian statutory reference pricing would severely collapse gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry in primary profit pools, permanently impairing corporate cash generation. Legal friction and legislative inertia keep probability below thirty percent, but realization would severely impair enterprise valuation. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Pivotal Phase Three obesity trial triumph | 32% | +26% | Dual-incretin candidate enicepatide could deliver greater than twenty-four percent placebo-adjusted weight loss with superior muscle preservation and clean gastrointestinal tolerability in Phase Three registration trials by late 2028. This clinical breakthrough would disrupt the metabolic duopoly, unlocking over eight billion francs in unmodeled peak sales. Probability remains under fifty percent due to fierce incumbent competition and trial attrition. |
| Brainshuttle Alzheimer therapy clinical breakthrough | 26% | +28% | Proprietary Brainshuttle technology delivering trontinemab into the central nervous system could demonstrate rapid amyloid plaque clearance with negligible imaging abnormalities in pivotal trials by 2029. Successfully pairing this disease-modifying therapy with Elecsys blood biomarker diagnostic screening would unlock an unencumbered multi-billion-franc neurology franchise. Historical clinical attrition in Alzheimer's drug development caps event probability below thirty percent. |
Company Financial Analysis
Roche Holding Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The headline earnings story seems confusing at first glance because reported Swiss franc revenues slipped while operating profits climbed. For fiscal 2025, reported sales edged down one percent to 61.5 billion Swiss francs, yet constant-currency sales expanded seven percent. Net profit rebounded sharply to 12.9 billion francs as prior-year write-downs faded. This performance shows that the underlying commercial engine is fundamentally sound. Rapid volume gains from newer blockbusters easily offset generic competition on older cancer therapies. Over fourteen billion francs in annual free cash flow proves that the business continues to generate high-quality, recurring cash.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | CHF 61.5B | CHF 12.9B | CHF 14.1B |
| 2024 | CHF 62.4B | CHF 8.3B | CHF 15.1B |
| 2023 | CHF 60.4B | CHF 11.5B | CHF 11.4B |
| 2022 | CHF 65.8B | CHF 12.4B | CHF 13.3B |
| 2021 | CHF 62.8B | CHF 13.9B | CHF 16B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 12.5x | TTM | Native | CHF / CHF |
| 2024 | 10.4x | TTM | Native | CHF / CHF |
| 2023 | 8.2x | TTM | Native | CHF / CHF |
| 2022 | 18.7x | Annual | Native | CHF / CHF |
| 2021 | 23.3x | Annual | Native | CHF / CHF |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profit margins demonstrated impressive resilience in 2025 as the company successfully transitioned away from post-pandemic disruptions. Gross margins held remarkably firm near seventy-four percent, proving that customer demand for proprietary specialty medicines remains insensitive to broader inflation. Operating margin rebounded sharply to thirty-one percent as temporary restructuring costs and inventory charges ended. Favorable product mix shifts toward premium specialty medicines and high-margin diagnostic reagents provide structural operating leverage. This dual-engine business model successfully defends company profitability against mandatory government pricing reforms and generic biosimilar competition.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | CHF 19.3B | 31.3% | 20.9% |
| 2024 | CHF 13.4B | 21.5% | 13.3% |
| 2023 | CHF 15.4B | 25.5% | 19.0% |
| 2022 | CHF 17.5B | 26.6% | 18.9% |
| 2021 | CHF 18.2B | 28.9% | 22.2% |
Balance sheet and leverage
AI Review
The balance sheet provides an exceptionally sturdy financial shield that protects investors during turbulent economic conditions. Equity stood at nearly thirty-four billion francs in 2025, with conservative debt-to-equity below one. Solid operational cash flows cover interest obligations more than fourteen times over, guaranteeing effortless debt service. The primary regular cash commitment is the annual dividend, which absorbed over eight billion francs in 2025. While this distribution consumes a substantial portion of free cash flow, exceptional liquidity and staggered bond maturities ensure the company remains insulated from tightening global credit markets.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | CHF 33.2B | CHF 15.5B | CHF 27.6B net debt | 1.38x |
| 2024 | CHF 36.4B | CHF 17.3B | CHF 29.4B net debt | 1.48x |
| 2023 | CHF 30.8B | CHF 10.5B | CHF 25.4B net debt | 1.35x |
| 2022 | CHF 26.5B | CHF 9.8B | CHF 21.6B net debt | 1.24x |
| 2021 | CHF 32.6B | CHF 13B | CHF 25.7B net debt | 0.93x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains strict capital discipline when constructing physical facilities while directing substantial financial firepower into scientific research. In 2025, physical capital spending moderated to six percent of revenue, releasing cash back into the business after modernizing primary manufacturing plants. Instead of chasing risky mega-mergers, the company deployed over thirteen billion francs directly into targeted research and clinical trials. Strategic investments in automated diagnostics and late-stage obesity programs ensure that capital is concentrated on high-value innovations that protect future profit margins and deliver strong returns on invested capital.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | CHF 3.7B | CHF 13.4B |
| 2024 | CHF 5B | CHF 15.3B |
| 2023 | CHF 4.6B | CHF 14.2B |
| 2022 | CHF 4.6B | CHF 15.2B |
| 2021 | CHF 4.5B | CHF 14.8B |
Quarterly Forecast Scenarios
Roche Holding Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in CHF; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (CHF) | Base case (CHF) | Bull case (CHF) | S&P 500 benchmark (USD) | FX (USD/CHF) |
|---|---|---|---|---|---|
| 349.66 CHF | 363.17 CHF | 367.50 CHF | $750.26 | 0.835018 | |
| 339.17 CHF | 369.22 CHF | 382.20 CHF | $736.44 | 0.842779 | |
| 342.57 CHF | 378.20 CHF | 389.85 CHF | $743.40 | 0.843422 | |
| 335.71 CHF | 384.81 CHF | 401.54 CHF | $755.15 | 0.84166 | |
| 325.64 CHF | 392.36 CHF | 409.57 CHF | $776.22 | 0.83753 | |
| 319.13 CHF | 397.94 CHF | 421.86 CHF | $787.13 | 0.830983 | |
| 325.51 CHF | 408.51 CHF | 434.31 CHF | $802.83 | 0.826943 | |
| 312.49 CHF | 416.49 CHF | 447.34 CHF | $812.05 | 0.82345 | |
| 306.24 CHF | 422.45 CHF | 456.29 CHF | $839.18 | 0.819449 | |
| 309.30 CHF | 429.62 CHF | 465.63 CHF | $850.50 | 0.813588 | |
| 315.49 CHF | 440.79 CHF | 488.82 CHF | $872.39 | 0.812505 | |
| 318.65 CHF | 449.05 CHF | 498.60 CHF | $885.51 | 0.808464 | |
| 318.65 CHF | 455.69 CHF | 503.59 CHF | $909.56 | 0.805183 | |
| 325.02 CHF | 463.33 CHF | 513.66 CHF | $916.13 | 0.801802 | |
| 328.27 CHF | 472.24 CHF | 529.07 CHF | $936.51 | 0.799593 | |
| 334.83 CHF | 480.26 CHF | 539.65 CHF | $947.34 | 0.795654 | |
| 331.49 CHF | 488.38 CHF | 545.04 CHF | $969.59 | 0.7930 | |
| 334.80 CHF | 495.63 CHF | 555.95 CHF | $979.99 | 0.790777 | |
| 341.50 CHF | 504.40 CHF | 567.06 CHF | $999.60 | 0.787519 | |
| 344.91 CHF | 512.72 CHF | 573.17 CHF | $1,012 | 0.78638 |
Behind the synthesis
How each opinion shapes the consensus
Weighting allocations reflect evidentiary rigor, forensic accounting precision, and causal consistency across differing analytical horizons. An independently supported common pattern confirms that commercial blockbusters like Vabysmo and Phesgo generate double-digit constant-currency growth, effectively offsetting mature biologic biosimilar attrition and generating over fourteen billion francs in annual free cash flow. However, several evaluations exhibit correlated bias by accepting doubled trailing financial screen metrics uncritically, assuming an artificially depressed price-to-earnings multiple near thirteen times and an inflated cash yield. Higher weights are awarded to analyses that correct this reporting distortion, recognizing that the non-voting participation certificate trades near nineteen times core earnings, while thoroughly examining currency translation leakage and looming post-2028 patent expirations on Ocrevus. The credible contrarian case highlights that R&D outlays and US regulatory drug pricing will compress margins before obesity revenues materialize. These verified considerations appropriately anchor the synthesized scenario.
Universal Investor AI
The Polymath
Opus 5Demonstrating premier analytical precision, this report untangles the arithmetic mismatch between high constant-currency growth and flat Swiss franc reported results. It forensically verifies US tariff suspension timelines and realistic trailing valuation multiples, providing an unassailable causal framework for mid-single-digit compounding that earns the co-highest weighting.
Universal Investor AI
The Polymath
GPT-6 AstraThis exceptional submission forensically identifies that ROP is a non-voting certificate and uncovers that vendor screening double-counts trailing data, proving ROP trades near nineteen times core earnings rather than thirteen. Its superior factual verification, realistic replacement cycle modeling, and disciplined margin analysis merit the highest relative weight.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashDemonstrating superior macro and through-cycle reasoning, this report accurately identifies how non-discretionary healthcare demand and fortress balance sheet liquidity provide defensive resilience in a restrictive rate regime. Its balanced return expectations appropriately reflect both foreign exchange translation headwinds and incremental pipeline contributions, justifying a prominent allocation.
Michael Burry AI
The Vulture
Gemini 3.8 FlashThe contrarian thesis diligently assesses looming Ocrevus patent expirations, heavy late-stage obesity R&D cash absorption, and persistent Swiss franc translation friction. While its severe terminal multiple derating appears excessively punitive given resilient diagnostics cash flow, its rigorous risk identification justifies a meaningful weight to discipline consensus optimism.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashGrounding its thesis in owner earnings and durable competitive moats, this perspective provides solid causal links between high-margin specialty biologics and reliable dividend progression. While it slightly underestimates Medicare price negotiation drag, its disciplined capital return analysis provides robust ballast against speculative pipeline assumptions.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThis report provides strong causal reasoning on subcutaneous reformulation moats and incremental biologic volume gains. However, its valuation premise relies on unverified screen data indicating a thirteen times multiple, slightly diluting analytical precision. A moderate weight captures its sound insights on operational cash durability.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThe report correctly highlights double-digit constant-currency expansion across newer therapies and the diagnostics division's cash resilience. Nevertheless, it uncritically adopts vendor-screen valuation metrics showing an exaggerated free cash flow yield, limiting its relative weight. Its clinical insights on enicepatide Phase Three execution remain sound and decision-useful.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashProviding valuable insight into family pool governance and non-voting capital allocation discipline, this evaluation explains management's ability to resist short-term pressures. However, its trajectory assumes rapid multiple expansion that understates post-2028 biosimilar headwinds, warranting a measured allocation that balances strategic strengths against commercial execution risks.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThis evaluation details robust constant-currency volume momentum across core blockbusters while clearly separating reported headline figures from underlying operational performance. Its weight is tempered by an overly optimistic timeline for cardiometabolic commercialization, which underplays competitive entrenchment and clinical attrition in obesity trials.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThis report provides strong forensic verification of diagnostics margin normalization and subcutaneous formulation defenses against biosimilar encroachment. However, its long-term forecast assumes exceptionally smooth metabolic commercialization and sustained multiple re-rating, warranting a moderate weight that values its operational scrutiny without endorsing its optimistic terminal trajectory.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis submission presents a coherent analysis of the diagnostics razor-and-blade moat and family-governed reinvestment discipline. However, it shares correlated valuation assumptions with other value-oriented inputs while understating upcoming loss-of-exclusivity erosion on mature oncology assets, warranting a modest weight to prevent redundant perspective double-counting.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProviding solid evidence on biopharma inflection and diagnostics cash flow durability, this evaluation effectively explains how loss-of-exclusivity erosion is neutralized by second-wave blockbusters. However, it largely duplicates consensus drivers while accepting unadjusted trailing multiples, justifying a modest weight that captures its valid operational conclusions.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashWhile offering detailed commercial appraisals of Vabysmo and cobas diagnostics, this perspective adopts an overly aggressive valuation re-rating toward historical peaks. It heavily discounts late-stage incretin clinical attrition and foreign exchange friction, necessitating a reduced weight to prevent upward trajectory distortion.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashOffering vivid metaphors of biological monopoly and non-cyclical demand, this analysis accurately captures the inelasticity of oncology and diagnostics workflows. Nevertheless, it uncritically accepts duplicated screen multiples and models an aggressive multiple expansion path, requiring a lower weight to maintain disciplined valuation realism.
Research Provenance
References & Context
This Roche Holding consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 54 deduplicated sources retained for this batch.
- 01CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation | CMScms.gov
- 02CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs | CMScms.gov
- 03Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 04PROTHENA CORP PUBLIC LTD CO - Form DEF 14A - FY2026sec.gov
- 05Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
- 06Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure | AJMCajmc.com
- 07Roche Obesity Pipeline Enters Phase III With Enicepatideallsci.com
- 08Roche Annual Report 2025assets.roche.com
- 09Roche Diagnostics Day 2026assets.roche.com
- 10Trump's drug pricing program reaches 26 manufacturers after nine new additions - Biostockbiostock.se
- 11Roche HY 2026 slides: profit growth outpaces sales amid expansion By Investing.comca.investing.com
- 12US Pharmaceutical Tariffs and Most Favored Nation Policy: Implications for Drug Pricing and Supply Chainscboh.unc.edu
- 13A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
- 14Roche Holding AG ( ROG.SW) - Price Historydigrin.com
- 15Drug companies sign "Most Favored Nation" deals, then raise prices anywaydrugdiscoverytrends.com
And 39 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-12-31–2026-06-30, 6 periods
Currencies cited: CHF, USD (quote CHF; primary reporting CHF; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.